BioSpace News Archive

Stryker’s Spine division will showcase its expanding line of Tritanium® cages, including the new Tritanium® TL Curved Posterior Lumbar Cage, a 3D-printed interbody fusion cage intended for use as an aid in lumbar fixation, at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, April 28–May 2, 2018, in New Orleans.

ACADIA Pharmaceuticals Inc. announced poster presentations of clinical experience data from two studies of NUPLAZID® (pimavanserin) in Parkinson’s disease psychosis (PD Psychosis) at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles.

NeuroVive Pharmaceutical AB today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions follows.

AIDS Healthcare Foundation today is calling on United States Representative Chris Collins (R-NY) to recuse himself on any and all legislation that may affect any pharmaceutical company.

With the addition of GlycOCATCH, Genovis is expanding its already unique offering of products within the field of O-glycans and streangthens its position as an innovator in this market.

Moleculin Biotech, Inc., announced that Dr. Waldemar Priebe, Chair of the Company’s Scientific Advisory Board, has been selected to present findings on Moleculin’s STAT3 inhibitor and immuno-stimulating agent, WP1066, at the Global Academic Programs 2018 in Stockholm, Sweden in May of this year.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced five poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago, Illinois.

Announcement comes as Lyndra CEO Amy Schulman’s TEDMED talk is released to the public; Schulman featured as “visionary entrepreneur”

DZUVEO is AcelRx’s second developed sublingual sufentanil-based product to receive positive CHMP opinion, with Zalviso® already approved Resubmission of New Drug Application for DSUVIA™ (known as DZUVEO in Europe) to the FDA in the U.S. is planned for Q2 2018

Compugen Ltd. announced that the U.S. Food and Drug Administration (FDA) requested that the Company provide additional CMC information in support of its IND application for COM701.